|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Current assets | ||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||
| Prepaid Expenses | ||||||||||||||||||
| Due from Sponsor | ||||||||||||||||||
| Inventories | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total current assets | ||||||||||||||||||
| Assets held in Trust Account | ||||||||||||||||||
| Deferred financing costs | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| Liabilities and stockholders’ equity (deficit) | ||||||||||||||||||
| Current liabilities | ||||||||||||||||||
| Loan and Transfer notes payable | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total loan and Transfer notes payable | ||||||||||||||||||
| Financial Liability - SPAC loan | ||||||||||||||||||
| Subscription Agreement loan | ||||||||||||||||||
| Accounts payable | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total accounts payable | ||||||||||||||||||
| Accrued expenses | ||||||||||||||||||
| Due to affiliate | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Affiliates | ||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||
| Total due to affiliate | ||||||||||||||||||
| Notes payable – related party | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total notes payable – related party | ||||||||||||||||||
| Promissory note fee – related party | ||||||||||||||||||
| Derivative liability | ||||||||||||||||||
| Loan and transfer notes payable – related party | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total loan and transfer notes payable – related party | ||||||||||||||||||
| Subscription agreement loans | ||||||||||||||||||
| Convertible notes | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total current liabilities | ||||||||||||||||||
| Forward purchase agreement liability | ||||||||||||||||||
| Liabilities | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Class A ordinary shares subject to possible redemption at redemption value, $0.0001 par value, 577,644 and 1,803,729 shares at redemption value of $11.54 and $ 11.03 per share on December 31, 2024 and 2023, respectively | ||||||||||||||||||
| Total class A ordinary shares subject to possible redemption at redemption value, $0.0001 par value, 577,644 and 1,803,729 shares at redemption value of $11.54 and $ 11.03 per share on December 31, 2024 and 2023, respectively | ||||||||||||||||||
| Stockholders’ equity (deficit) | ||||||||||||||||||
| Series A convertible preferred stock, 30,000 and 0 shares as designated, respectively, $0.0001 par value; 17,050 and 0 shares issued or outstanding, respectively | ||||||||||||||||||
| Common stock; $0.0001 par value; 490,000,000 shares authorized; 1,295,234 and 117,780 issued and outstanding, respectively | ||||||||||||||||||
| Common Class A | ||||||||||||||||||
| Total common Class A | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total common stock; $0.0001 par value; 490,000,000 shares authorized; 1,295,234 and 117,780 issued and outstanding, respectively | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total additional paid-in capital | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total accumulated deficit | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total stockholders’ equity (deficit) | ||||||||||||||||||
| Aspire Biopharma Inc | ||||||||||||||||||
| Total liabilities and stockholders’ equity (deficit) | ||||||||||||||||||
Loading...
